Oncobiologics (OTLK) Competitors $2.31 -0.10 (-4.15%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$2.28 -0.04 (-1.52%) As of 07/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. PVLA, ABEO, LFCR, ALDX, VOR, CRVS, SGMT, DBVT, ANNX, and AVTEShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Palvella Therapeutics (PVLA), Abeona Therapeutics (ABEO), Lifecore Biomedical (LFCR), Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Palvella Therapeutics Abeona Therapeutics Lifecore Biomedical Aldeyra Therapeutics Vor Biopharma Corvus Pharmaceuticals Sagimet Biosciences DBV Technologies Annexon Aerovate Therapeutics Oncobiologics (NASDAQ:OTLK) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Does the media refer more to OTLK or PVLA? In the previous week, Oncobiologics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 2 mentions for Oncobiologics and 0 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.89 beat Oncobiologics' score of 1.08 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Oncobiologics Positive Palvella Therapeutics Very Positive Which has more volatility and risk, OTLK or PVLA? Oncobiologics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Which has stronger valuation & earnings, OTLK or PVLA? Palvella Therapeutics has higher revenue and earnings than Oncobiologics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.91-2.54Palvella Therapeutics$42.81M8.07-$17.43M-$12.10-2.58 Is OTLK or PVLA more profitable? Oncobiologics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -271.12% Palvella Therapeutics N/A -60.29%-43.30% Do institutionals and insiders have more ownership in OTLK or PVLA? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate OTLK or PVLA? Oncobiologics currently has a consensus target price of $9.60, suggesting a potential upside of 315.58%. Palvella Therapeutics has a consensus target price of $46.29, suggesting a potential upside of 48.21%. Given Oncobiologics' higher probable upside, equities research analysts clearly believe Oncobiologics is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryPalvella Therapeutics beats Oncobiologics on 9 of the 15 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.90M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-2.5420.2928.1019.86Price / SalesN/A302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book-0.757.838.265.67Net Income-$75.37M-$55.11M$3.24B$257.80M7 Day Performance11.59%3.21%1.48%1.87%1 Month Performance37.50%12.86%8.07%10.92%1 Year Performance-71.52%5.06%30.29%18.51% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.5356 of 5 stars$2.31-4.1%$9.60+315.6%-74.2%$80.90MN/A-2.5420Positive NewsPVLAPalvella Therapeutics2.5393 of 5 stars$27.55+4.1%$46.29+68.0%N/A$304.59MN/A-2.28N/APositive NewsABEOAbeona Therapeutics3.7509 of 5 stars$5.92+3.1%$19.25+225.2%+22.3%$302.87M$3.50M-4.6690LFCRLifecore Biomedical1.3528 of 5 stars$8.17-1.6%$8.00-2.1%+38.1%$302.49M$130.31M-5.63690News CoverageALDXAldeyra Therapeutics2.385 of 5 stars$5.01+7.7%$9.50+89.6%+23.6%$300.08MN/A-5.1610News CoverageVORVor Biopharma3.5305 of 5 stars$2.39-4.4%$5.63+135.5%+138.8%$298.65MN/A-1.45140CRVSCorvus Pharmaceuticals2.8704 of 5 stars$4.35+5.1%$15.00+244.8%+95.9%$296.54MN/A-4.4430Positive NewsSGMTSagimet Biosciences2.3509 of 5 stars$9.46-0.1%$26.60+181.2%+180.9%$290.14M$2M-5.388News CoverageDBVTDBV Technologies3.858 of 5 stars$10.58-2.1%$14.75+39.5%+142.8%$289.68M$4.15M-2.1580Positive NewsANNXAnnexon2.2533 of 5 stars$2.61+1.2%$12.50+378.9%-60.1%$286.34MN/A-2.2160AVTEAerovate TherapeuticsN/A$9.82-6.7%N/A-86.7%$284.63MN/A-3.2820High Trading Volume Related Companies and Tools Related Companies Palvella Therapeutics Competitors Abeona Therapeutics Competitors Lifecore Biomedical Competitors Aldeyra Therapeutics Competitors Vor Biopharma Competitors Corvus Pharmaceuticals Competitors Sagimet Biosciences Competitors DBV Technologies Competitors Annexon Competitors Aerovate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
